Senseonics Holdings, Inc. (SENS) witnessed an after-hours plunge of 5.76% on Monday, following the release of its fourth quarter and full-year 2024 financial results.
The medical technology company reported a relatively modest increase in revenue for the fourth quarter and full year 2024, with Q4 revenue reaching $8.3 million, up from $8.0 million in Q4 2023, and full-year revenue of $22.5 million, slightly higher than $22.4 million in 2023. However, the company's net losses continued to widen.
For the full year 2024, Senseonics reported a net loss of $78.6 million, or $0.12 per share, a significant increase from the net loss of $60.4 million, or $0.11 per share, in 2023. While the company cited a reduction in gains due to the exchange of outstanding convertible notes and changes in the fair value of derivatives as contributing factors, the widening losses appear to have disappointed investors despite the revenue growth.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。